BLBo Lin

Bo Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bo Lin has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Yueming Liu

    Urology and Nephrology Center, Department of Nephrology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, China

    5 shared publications
  • Danna Zheng

    Urology and Nephrology Center, Department of Nephrology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, China

    3 shared publications
  • Qiang He

    Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)

    3 shared publications
  • Wei Shen

    Zhejiang Provincial People’s Hospital( Affiliated People’s Hospital, Hangzhou Medical College

    3 shared publications
  • Chengzhong Peng

    Department of Ultrasound, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, China

    2 shared publications
  • Haojie Liu

    The 2nd Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China

    2 shared publications

Latest Publications

  • A case of normolipidemic lipoprotein glomerulopathy due to the APOE Kyoto variant

    by Jihao Xu, Wenli Zou, Bo Lin, Bin Zhu, Jianguang Gong

  • Open Access

    Promising response of proliferative glomerulonephritis with monoclonal IgG deposits to low-dose daratumumab: a case report

    by Hongyao Xu, Yao Huang, Ling Dong, Hua Yu, Bo Lin

    Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare disease without standardized treatment modalities. Daratumumab is a human IgG monoclonal anti-CD38 antibody that has been demonstrated to be highly effective and safe in the treatment of PGNMID. This article reports a 66-year-old female who suffered from edema in both lower limbs and face for 6 years with mild proteinuria and hypoproteinemia. Renal biopsy displayed eight glomeruli, among which two presented with glomerulosclerosis, and the remaining six exhibited moderate diffuse hyperplasia of glomerular mesangial cells and stroma with endothelial cell proliferation. Immunofluorescence microscopy revealed lumpy and diffuse deposits of C3, C1q, IgG, and κ light chain in the glomerular mesangium, with strongly positive staining for IgG3 and varying degrees of weak to negative staining for IgG1, IgG2, IgG4, and λ light chain. Additionally, ultrastructural analysis unveiled that the glomerular basement membrane was segmentally thickened, accompanied by diffuse pedicle fusion, segmental tethered insertion, subendothelial deposits, and electron-dense material in tethered areas. The patient received a total dose of 800 mg of daratumumab (400 mg daily for two consecutive days), as well as daily prednisone (25 mg) and valsartan (80 mg), for treatment and achieved complete remission after three-month follow-up. This case represents an early attempt to treat PGNMID with low-dose daratumumab but requires long-term follow-up.


  • Open Access

    Misdiagnosis of chronic kidney disease and parathyroid hormone testing during the past 16 years

    by Haojie Liu, Huan Zhao, Danna Zheng, Wenfang He, Yueming Liu, Juan Jin, Qiang He, Bo Lin

    Chronic kidney disease (CKD) is a prevalent pathological condition worldwide. Parathyroid hormone (PTH) is an important index related to bone metabolism in CKD patients and has not received enough attention. This study was performed to investigate the incidence and diagnostic rate of CKDin hospital as well as PTH testing and treatment for secondary hyperparathyroidism (SHPT) in patients with stage 3 to 5 CKD. The data of patients who visited Zhejiang Provincial People's Hospital from February 2006 to April 2022 were retrieved from the hospital database. All data were divided into three subgroups using PTH testing and SHPT treatment as major comparative indicators for analysis. The data were then analyzed for overall PTH testing, CKD incidence, and diagnostic rate. Among 5,301,391 patients, the incidence of CKD was 13.14%. The missed diagnosis rate for CKD was 65.76%. The total PTH testing rate was 1.22%, of which 15.37% of PTH testing was performed in patients with stage 3 to 5 CKD. The overall diagnosis rate of SHPT in patients with stage 3 to 5 CKD was 31.0%. The prophylactic medication rate was 7.4%, and the rate of post-diagnostic drug therapy was 22.2% in patients who underwent SHPT treatment. The high misdiagnosis rate and low PTH testing rate of CKD requires prompt attention from clinicians. SHPT treatment should be considered especially in patients with stage 3 to 5 CKD.


  • Open Access

    Gut microbiota dysbiosis and increased plasma trimethylamine N-oxide in patients with chronic kidney disease

    by Wenli Zou, Yueming Liu, Wei Zhang, Wei Shen, Bo Lin

    Background The gut microbiota has been identified as a source of pathogenic mediators in chronic kidney disease (CKD). A gut microbiota-dependent metabolite, trimethylamine N-oxide (TMAO), has been reported to be closely related to CKD complications. This study aimed to investigate the changes in intestinal microbiota and circulating levels of TMAO in Chinese patients with CKD. Methods The study comprised 50 paticipants including 30 patients with CKD and a control group of 20 healthy controls. Plasma TMAO levels were detected by high-performance liquid chromatography-tandem mass spectrometry, and gut microbiota was analysed using High-throughput sequencing. Results Compared to the healthy control group, the CKD patients had relatively lower albumin and hemoglobin levels and showed obviously impaired renal function and abnormal urine test results. Additionally, CKD patients showed increased plasma TMAO levels, especially those with a low glomerular filtration rate (GFR). Among the biochemical indices of the CKD patients, impaired renal function was the main contributor of the increased TMAO levels. High-throughput sequencing revealed obvious gut dysbiosis in CKD patients with biased community constitutions. Based on the Pearson correlation analysis, many bacteria positively or negatively correlated with TMAO production at the phylum and genus levels. Conclusions Our study demonstrated that gut microbiota dysbiosis and decreased GFR were the main causes of plasma TMAO level. Elevation, and inhibition of intestinal metabolite TMAO production may be the key to preventing CKD progression.

  • Open Access

    Comparison of the prophylactic antithrombotic effect of indobufen and warfarin in patients with nephrotic syndrome: a randomized controlled trial

    by Xin-Yi Gao, Yue-Ming Liu, Dan-Na Zheng, Yi-Wen Li, Hua Li, Xiao-Ling Xiong, Hong-Yu Chen, Hua Wang, Xiao-Yong Yu, Kai Qu, et al.

    The risk of thromboembolic events is elevated in patients with nephrotic syndrome, and warfarin use has been associated with an increased risk of bleeding. Indobufen, a selective cyclooxygenase-1 i...


  • Open Access

    The role of extracellular vesicles in vascular calcification in chronic kidney disease

    by Huan Zhao, Haojie Liu, Yueming Liu, Juan Jin, Qiang He, Bo Lin

    Widespread vascular calcification (VC) in patients with chronic kidney disease (CKD) is the pathological basis for the development of cardiovascular disease, and VC has been identified as an independent risk factor for increased cardiovascular mortality in cases of CKD. While VC was earlier thought to be a passive deposition process following calcium and phosphorus supersaturation, recent studies have suggested that it is an active, modifiable, biological process similar to bone development. The involvement of extracellular vesicles (EVs) in the process of VC has been reported as an important transporter of material transport and intercellular communication. This paper reviews the mechanism of the role of EVs, especially exosomes, in VC and the regulation of VC by stem cell-derived EVs, and discusses the possible and promising application of related therapeutic targets in the clinical setting.


  • Open Access

    Efficacy and safety of radiofrequency ablation versus parathyroidectomy for secondary hyperparathyroidism in dialysis patients: a single-center retrospective study

    by Mian Ren, Danna Zheng, Juan Wu, Yueming Liu, Chengzhong Peng, Wei Shen, Bo Lin

    We compared the efficacy and safety of ultrasound (US)-guided radiofrequency ablation (RFA) and parathyroidectomy (PTX) for the treatment of secondary hyperparathyroidism (SHPT). In this single-center retrospective study, we divided patients into PTX (n = 53) and RFA (n = 47) groups. The primary outcome was the proportion of patients who achieved the target intact parathyroid hormone (iPTH) concentration range (≤ 300 pg/mL). Secondary outcomes were the differences in the changes in iPTH, calcium, and phosphorus levels over time and prognosis. iPTH concentrations of 82.1% and 64.1% in the PTX and RFA groups, respectively, were within the recommended range at the endpoint (P = 0.07). iPTH concentrations in the PTX and RFA groups dropped sharply after treatment (82 ± 163 pg/mL and 280 ± 307 pg/mL, respectively, P < 0.001). There was no difference in the trends of iPTH, calcium, and phosphorus levels between the two groups (P > 0.05). Survival analysis revealed no differences in all-cause mortality and cumulative response rate between the two groups (P = 0.90, P = 0.14, respectively). Notably, the incidence of infection and length of the hospital stay in the RFA group were significantly lower. The preoperative bone-specific alkaline phosphatase concentration was a risk factor for postoperative hypocalcemia. US-guided RFA is minimally invasive and compared to PTX in terms of long-term efficacy and complications in the treatment of severe SHPT in maintenance dialysis patients. It may be used as an alternative technique to PTX; however, further studies are needed.


  • Open Access

    Recommend-Response and Complications Comparing Radiofrequency Ablation Versus Parathyroidectomy for Secondary Hyperparathyroidism in Dialysis Patients

    by Mian Ren, Danna Zheng, Juan Wu, Yueming Liu, Chengzhong Peng, Wei Shen, Bo Lin

    Introduction : To compare the efficacy and safety of ultrasound(US)-guided radiofrequency ablation (RFA) and parathyroidectomy (PTX) in the treatment of secondary hyperparathyroidism (SHPT). Methods In this retrospective study, we divided patients into PTX (n=53) and RFA (n=47) groups. The primary outcomes were the proportion of patients achieved the target range of iPTH concentrations(124-558pg/mL) and the long-term prognosis. The secondary outcomes were the differences in the changes of iPTH, calcium, and phosphorus over time and the incidence of adverse events. Results There was rarely difference in baseline characteristics between the two groups. Primary outcomes: The iPTH concentrations of 25.8% of patients in the PTX group and 51.3% of the RFA group were within the recommended range at the endpoint (P=0.031). Survival analysis revealed that the difference in all-cause mortality and cumulative response rate between the two groups was not statistically significant (P=0.902, P=0.141, respectively). Secondary outcomes: The iPTH concentrations in PTX group and RFA group dropped sharply after treatment and were 82.30±163.21pg/mL and 279.96±306.57pg/mL (P0.05). In addition, the incidence of infection and the hospital stay in the RFA group were significantly less. And preoperative bone-specific alkaline phosphatase concentration was a risk factor for postoperative hypocalcemia. Conclusion US-guided RFA was minimally invasive and no less than PTX in terms of cumulative response rate and complications in the treatment of severe SHPT in maintenance dialysis patients and may be used as an alternative technique to PTX, which need further studies to confirm.

  • Open Access

    Prevalence of chronic kidney disease and its association with metabolic diseases: a cross-sectional survey in Zhejiang province, Eastern China

    by Bo Lin, Lina Shao, Qun Luo, Lingxia Ou-Yang, Fangfang Zhou, Biao Du, Qiang He, Jianyong Wu, Nan Xu, Jianghua Chen

    The prevalence of chronic kidney disease (CKD) and metabolic diseases has increased at different rates in different regions in China. The aim of our study was to estimate the prevalence of CKD and to analyze associated risk factors of CKD in Zhejiang province, Eastern China. A cross-sectional survey of 11,013 adults was conducted from September 2009 to June 2012 in Zhejiang Province, located in Eastern China. CKD was defined as having an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 or the presence of albuminuria. Medical history, physical examination and laboratory data were used to diagnose metabolic diseases. Age- and sex-standardized prevalence was calculated using the data on the population distribution in China in 2010. We examined risk factors associated with decreased renal function and albuminuria using multivariate logistic regression. A total of 10,384 adults (94.3%) completed the screening. The standardized prevalence of reduced renal function (eGFR < 60 mL/min/1.73 m2) was 1.83% (95% CI 1.52–2.13) and that of albuminuria was 8.65% (95% CI 7.98–9.31). The overall prevalence of CKD was 9.88% (95% CI 9.18–10.59). The prevalence of reduced renal function was greater in the eastern rural areas in Zhejiang province. Multivariate logistic regression revealed that metabolic diseases such as diabetes, obesity, hypertension, and hyperuricemia were independent risk factors of CKD. Patients with metabolic diseases had a significantly (P < 0.001) higher prevalence of CKD than those without such diseases. CKD has become a severe public health problem in Zhejiang Province, and metabolic diseases may increase the risk of CKD in Zhejiang population.